Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-7-27
pubmed:abstractText
The aim of this study was to examine the risk of cardiovascular diseases among users of both inhaled (ipratropium bromide or tiotropium bromide) and oral (oxybutynin and propantheline, solifenacin, tolterodine) anticholinergics.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1479-1072
pubmed:author
pubmed:issnType
Print
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
189-99
pubmed:meshHeading
pubmed-meshheading:20659403-Administration, Inhalation, pubmed-meshheading:20659403-Administration, Oral, pubmed-meshheading:20659403-Aged, pubmed-meshheading:20659403-Aged, 80 and over, pubmed-meshheading:20659403-Bronchodilator Agents, pubmed-meshheading:20659403-Cardiovascular Diseases, pubmed-meshheading:20659403-Cerebrovascular Disorders, pubmed-meshheading:20659403-Cholinergic Antagonists, pubmed-meshheading:20659403-Female, pubmed-meshheading:20659403-Humans, pubmed-meshheading:20659403-Logistic Models, pubmed-meshheading:20659403-Male, pubmed-meshheading:20659403-Middle Aged, pubmed-meshheading:20659403-Multivariate Analysis, pubmed-meshheading:20659403-Retrospective Studies, pubmed-meshheading:20659403-Risk, pubmed-meshheading:20659403-Scopolamine Derivatives, pubmed-meshheading:20659403-Stroke
pubmed:year
2010
pubmed:articleTitle
Comparison of risk of neurovascular and cardiovascular side effects between tiotropium and other anticholinergic agents.
pubmed:affiliation
Curtin University of Technology, Perth, Australia.
pubmed:publicationType
Journal Article, Comparative Study